Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887200 | 1.00 | CTSS (0.49) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL5887534 | 0.90 | CTSS (0.53) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL5887530 | 0.90 | CTSS (0.53) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL16459371 | 0.89 | PPARA (0.51) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL16470394 | 0.89 | CTSS (0.62) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL16459373 | 0.89 | PPARA (0.51) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL31571430 | 0.88 | KLK5 (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL1133288 | 0.88 | KLK5 (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL1133286 | 0.88 | KLK5 (0.57) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL5887479 | 0.88 | CTSS (0.63) | CTSSCTSKCTSBCTSLITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | CTSS 1702/4885CTSK 2430/4885CTSB 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.